Navigation Links
Microfluidic analysis of multiplex,,,PCR products for the genotyping of,,,Helicobacter pylori

Gastric infection with Helicobacter pylori (H. pylori) is the major cause of chronic active gastritis and is associated with the pathogenesis of peptic ulcer and gastric carcinoma. Recent studies using a multiplex PCR (mPCR) based approach distinguished different allelic variants that are associated with different stages of H. pylori virulence. H. pylori genotyping on gastric tissues, routinely processed in diagnostic pathology, revealed that certain combinations of virulence subtypes of different H. pylori sub-strains are associated with gastric carcinoma and MALT lymphoma. The use of formalin fixed samples as the source for template DNA for mPCR restricts the size of the PCR fragments to 300 bp, due to poor DNA quality. For the analysis of multiple bands of a mPCR experiment, the data acquisition from slab gels is often inconvenient in terms of sizing, resolution, and data accuracy. To improve accuracy and reproducibility of the measurements, the Agilent 2100 bioanalyzer using Lab-on-a-chip technology was tested to replace slab gels as the tool for the electrophoretic separation of the mPCR products. First analyses revealed an improved fragment resolution, sizing accuracy and reproducibility. A mPCR reaction covering five different alleles that are involved in H. pylori pathogenesis was analyzed and all fragments were separated and quantified. The analysis of a mixture of all mPCR reactions including all involved alleles showed the separation of seven different PCR fragments in the range of 102 to 301 bp, thereby expanding the spectrum of prognostic or therapeutically relevant information used e.g. in H. pylori diagnostic.
The human pathogen Helicobacter pylori (H. pylori) is associated with the development of a variety of gastro-duodenal diseases, such as chronic active gastritis, peptic ulcer disease, gastric cancer, and gastric mucosa associated lymphoid tissue (MALT) lymphoma1. It is estimated that about half of the world's population is infected with H. pylori. But despite the high prevalence of infections only a minority of infected individuals will develop gastric carcinoma or MALT lymphoma. Therefore, it is essential to identify factors that might determine the possible sequelae of the H. pylori infection, such as host and environmental factors and bacterial virulence genes.
The specific H. pylori virulence genes found to be associated with possible disease outcome are the various alleles of the vacA gene, the presence of the cagA gene as a marker for a pathogenicity island, and the allelic variants of the iceA gene. The vacA gene is present in all H. pylori strains and encodes for the vacuolating cytotoxin, VacA which causes vacuolar degeneration of gastric epithelial cells. The vacA gene, although present in all strains, differs in its allelic variants in the signal region and the mid-region of the gene. The sequence variations in the signal region are distinguished into vacA s1 and vacA s2 subtypes, and the mid-region can be distinguished into m1 or m2 subtypes2. The allelic variants of the vacA gene that were detected by nested PCR were vacAs1/m1, vacAs1/m2 and vacAs2/m2. These vacA gene variants are associated with different cytotoxin activities. The cagA gene is a marker for the presence of the cag pathogenicity island, which is a 40 kb locus containing 31 genes associated with the induction of interleukin 8 secretion by gastric epithelial cells3. The allelic variants of the iceA gene are distinguished into iceA1 or iceA2 and only one of which being found in all H. pylori strains. The iceA gene seems to be induced by contact with epithelium and associated with increased mucosal interleukin 8 concentrations4.
In our studies5, we have found that certain H. pylori subtype combinations of the vacA, cagA and iceA genes possess a differentiating and predictive value for the development of gastric adenocarcinoma and MALT lymphoma. We have established a multiplex PCR analysis to detect and distinguish the different H. pylori genes and their allelic variants from DNA extracted from paraffin wax embedded tissues. The use of template DNA derived from formalin fixed and paraffin wax embedded tissue for the mPCR restricts the size of the PCR fragments to a maximum of about 300 bp due to fragmentation and poor DNA quality from such tissue. The primer sets used in the mPCR for the detection of the different H. pylori virulence genes generated amplification products with a maximum length of 301 bp. The combined use of primer sets in the mPCR was possible because each primer set required an annealing temperature of 58 C and all PCR products were distinguishable by size on slab gel electrophoresis. In order to obtain more reproducible and standardized results, a microfluidic based analytical platform, the Agilent 2100 bioanalyzer, using lab-on-a-chip technology6 was tested to replace slab gels as the tool for the electrophoretic separation of the mPCR products.
Material and methods
Tissues
The paraffin embedded and formalin fixed gastric tissues from chronic gastritis, gastric adenocarcinoma and gastric MALT lymphoma specimen were recruited from the archives of the Institutes for Pathology of the University of Mainz (Germany) and Cologne (Germany). Three 5-7 m-sections of each specimen were de-waxed in xylene and the nucleic acids were extracted by phenol/chloroform followed by precipitation in 300 mM sodium acetate and 50 % isopropanol.
PCR
For H. pylori genotyping, a sequence specific, nested PCR approach was performed as described earlier by Koehler et al. [5]. Briefly, genomic sub-fragments of the virulence factors vacA, cagA, and iceA were amplified by the combined use of allelespecific primer sets (vacA s1/s2, vacA m1/m2, cagA, and iceA 1/2) in two PCR amplification steps, each starting with a preincubation at 95C for 5 minutes, then followed by 35 cycles of 1 minute denaturation at 95 C, 1 minute annealing at 58 C and 1 minute extension at 72 C. PCR yielded products with sizes varying from 102 bp to 301 bp.
Analysis of PCR-products
PCR products were analyzed using standard agarose gel electrophoresis and Lab-on-a-chip technology on the Agilent 2100 bioanalyzer using the Agilent DNA 1000 LabChip kit according to the manufacturer's instructions.
Results and discussion
In a previous study 5 we have established a nested multiplex PCR (mPCR) assay in order to identify the different virulence factors of Helicobacter pylori, vacA, cagA and iceA genotypes in routinely processed gastric biopsies which are formalin fixed and paraffin embedded. The nested mPCR assays with a limited number of primer sets produced reliable, distinct amplification products of all specimens. The combined PCR assays for the simultaneous detection of the vacA midregions m1 and m2, as well as the combined detection of iceA1 and iceA2 were routinely performed. The semi-nested PCR for the detection of the vacA signal regions s1 and s2 was usually combined with the nested PCR for the cagA gene. The established mPCR assay permits the simultaneous analysis of all seven different diagnostically relevant alleles. However, tested on a broad spectrum of diagnostic samples and analysed on a standard agarose gel, the assay resulted in PCR fragment patterns that were difficult to interpret in some cases.
To increase analytical precision of these studies the Agilent 2100 bioanalyzer, using Lab-on-a-chip technology was tested to replace slab gels as the tool for the electrophoretic separation and analysis of the mPCR products. First, we compared the analysis of the routinely performed combined PCRs of vacAs1/s2/cagA, of vac- Am1/m2 (data not shown) and of iceA1/2 (figure 1) on the Agilent 2100 bioanalyzer with slab gel results. The microfluidic analysis of the PCR amplicons of the H. pylori virulence genes showed and confirmed the results of our samples as imaged by slab gel electrophoresis. Especially the improved fragment resolution by the Agilent 2100 bioanalyzer (figure 1B) compared with the slab gel analysis (figure 1A) and the representation as an electropherogram (figure 1C) were helpful in differentiating DNA fragments, which differ in size by only 29 bp as with iceA1 and iceA2 (figure 1).

Next, the combined analysis of the five different alleles (vacA s1 or s2, cagA, vacA m1 or m2) was investigated (figure 2). Whereas the detection of the 5 alleles of H. pylori genotypes was sometimes difficult when imaging was performed with slab gel electrophoresis the imaging of microfluidic data showed improved analysis of distinct amplification products. The gel-like image shows the separation of vacAs2/vacAm2 in lane 1 and 4 and vacAs1/cagA/vacAm1 in lane 2 and 3 (figure 2A). The analysis resulted in calculated sizes of 98 and 101 bp for the vacAm2 amplicon and in calculated sizes of 151 and 148 bp for the vacAs2 amplicon (expected sizes: vacAm2: 102 bp and vacAs2: 150 bp, respectively). In addition to the gel like image, the result of lane 1 and 2 of figure 2A are displayed as electropherograms (figures 2B and 2C).

Finally, combined microfluidic analysis of all 7 alleles of H. pylori amplified in 4 different mPCRs was possible on the chip after mixing all mPCR reactions prior to analysis (combination of: iceA1/A2, vacA s1/s2, cagA, vacA m1/m2). This is difficult with slab gel electrophoresis where differences in the amount of PCR products cause difficulties in data interpretation. All seven different mPCR products within a range of 102-301 bp could be separated and quantified (figure 3). These results reveal that Lab-on-a-chip technology enables the separation of seven different targets restricted to a size range up to 300 bp in a combined mPCR reaction.

Conclusion
The results of this study clearly demonstrate the ability of the Agilent 2100 bioanalyzer to differentiate the allelic H. pylori variations, vacAs1/s2/cagA, of vacAm1/m2 and of iceA1/2, amplified by mPCR. The high resolution achieved by the microfluidic based Lab-on-the-Chip technology allows to analyze a broad and expanding panel of virulence and risk factors. This is of great importance since an extended spectrum of prognostic or therapeutically relevant information used in H. pylori diagnostics will now be accessible for routinely processed simultaneous diagnostics by means of mRCR assays.



'"/>

Source:


Page: All 1 2 3 4 5 6

Related biology technology :

1. High-throughput gene expression analysis to screen for anti-asthma drugs
2. Fully automated DNA purification and efficient multiplex PCR for analysis of microsatellite loci
3. Flow cytometric analysis of human primary cells using the Agilent 2100 bioanalyzer and on-chip staining
4. 2100 expert software Powerful software for the analysis of RNA, DNA, proteins, and cells with the Agilent 2100 bioanalyzer
5. Using the Agilent 2100 bioanalyzer for quality control of protein samples prior to MS-analysis
6. High resolution DNA analysis with the DNA 500 and DNA 1000 LabChip kits
7. Extended data analysis using DeCyder EDA
8. 2D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ
9. Neurite outgrowth cell-by-cell analysis using the IN Cell Developer Toolbox
10. Laser Capture Microdissection of muscle fiber populations and expression analysis by RT-PCR
11. TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds
Post Your Comments:
(Date:7/30/2015)...   Senomyx , Inc. (NASDAQ: SNMX ), ... discover, develop, and commercialize novel flavor ingredients for the ... results for the second quarter 2015. ... on track to achieve our commercial and financial goals," ... the Company. "Since our last quarterly earnings report, our ...
(Date:7/30/2015)... LOUIS, July 30, 2015 HIGHLIGHTS:Q2 ... in 2014) , Reported sales were $697 million ... 2014.  Sales grew organically by 8%, and changes in ... acquisitions increased sales by 1%. , By business ... in Applied and 11% in SAFC Commercial. , ...
(Date:7/30/2015)... NH (PRWEB) , ... July 30, 2015 , ... ... homogenizer for advanced fluid applications and designed for continuous operation up to 1500 ... and sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L ...
(Date:7/29/2015)... 2015 According to a new market ... & Forecasts (2015-2020), , published by Mordor Intelligence, the Global ... the end of 2020, with North America ... 40% of the global market size. The Global market for ... 13.7% during the period of (2015-2020).      (Logo: ...
Breaking Biology Technology:SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3
... Enable CyberKnife Centers ... Demand for Radiosurgery, SUNNYVALE, Calif., Sept. 22 ... the field of radiosurgery,announced today that Oklahoma CyberKnife LLC, ... reduced treatment,planning and delivery times over the last two ...
... announced today,that its lead product ATIR(TM) has been ... Agency (EMEA) for the prevention of acute,Graft versus ... "Following the orphan drug designation granted by ... another important milestone in the development of,ATIR(TM) as ...
... China indicates that genetically modified cotton, altered to express the ... but also reduces pests among other nearby crops that have ... new ideas for controlling pests and maximizing crop yields in ... the journal Science on Friday, 19 September. ...
Cached Biology Technology:Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology 2Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology 3Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology 4EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation 2GM crops protect neighbors from pests 2
(Date:7/9/2015)...  Unchained Labs just can,t get enough biologics ... Nano. Avid Nano designs, develops and manufactures highly ... Also today, Unchained Labs UNcaged the pUNk, ... protein sizing system. The pUNk is a high-performance ... size distribution, aggregation population and molecular weight. Its ...
(Date:7/8/2015)... 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... announced the launch of a study that aims ... Monitoring℠ (PCM) technology for predicting response to treatment ... combination of the novel immunotherapy agents Yervoy® (ipilumumab), ... inhibitor. The 50-patient study will be led by ...
(Date:7/7/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... market announces a revised version of one of its first 30 ... on CNBC in New York , ... San Francisco metro areas.    , ... to replace all the cards in your wallet and keep your ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... The first study to analyze the complex ingredients in ... that these pop-into-the-mouth replacements for cigarettes in places where ... diseases and other problems. The report appears in ACS,s ... John V. Goodpaster and colleagues point out that the ...
... Mass. (March 16, 2011) Renowned cancer researchers Robert ... Hanahan, Director of the Swiss Institute for Experimental Cancer ... of Cancer," which has influenced the study of cancer ... decade. Published in January 2000, their original work, ...
... way the parasite that causes malaria reproduces could lead ... the disease. Scientists studying the disease have found ... from transmitting from person to person. Researchers at ... at a stage of its development in which it ...
Cached Biology News:New 'dissolvable tobacco' products may increase risk of mouth disease 2Whitehead scientist helps revisit 'Hallmarks of Cancer' 2Whitehead scientist helps revisit 'Hallmarks of Cancer' 3
...
Mouse Cell Line Slides...
Human Cell Line Slides...
... Detection System combines the indirect labeling ... and Signets unique formulation of ultra ... reliablility. Signet reagents will achieve excellent ... automated protocols. ,Signets USA Detection reagents ...
Biology Products: